| Title: |
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants : real-world evidence from MSBase |
| Authors: |
Spelman, Tim; Eichau, Sara; Alroughani, Raed; Ozakbas, Serkan; Khoury, Samia J; Patti, Francesco; Kubala Havrdova, Eva; Boz, Cavit; Terzi, Murat; Kuhle, Jens; Grammond, Pierre; Lechner-Scott, Jeanette; Gray, Orla; Amato, Maria Pia; Laureys, Guy; Shaygannejad, Vahid; Hyde, Robert; Wang, Haijue; Bozin, Ivan; Belviso, Nicholas; Quan, Chao; Zeng, Feng; van der Walt, Anneke; Butzkueven, Helmut; the MSBase Study Group, missing |
| Source: |
MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL TRANSLATIONAL AND CLINICAL ; ISSN: 2055-2173 |
| Publication Year: |
2024 |
| Collection: |
Ghent University Academic Bibliography |
| Subject Terms: |
Medicine and Health Sciences; Dimethyl fumarate; non-specific immunosuppressants; relapsing-remitting multiple sclerosis; real-world; effectiveness; REMITTING MULTIPLE-SCLEROSIS; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12; AZATHIOPRINE; INDUCTION; THERAPIES; CANCER; RISK |
| Description: |
Background The use of non-specific immunosuppressants (NSIS) to treat multiple sclerosis (MS) remains prevalent in certain geographies despite safety concerns, likely due to resource limitations. Objective To use MSBase registry data to compare real-world outcomes in adults with relapsing-remitting MS (RRMS) treated with dimethyl fumarate (DMF) or NSIS (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mitoxantrone or mycophenolate mofetil) between January 1, 2014 and April 1, 2022. Methods Treatment outcomes were compared using inverse probability of treatment weighting (IPTW) Cox regression. Outcomes were annualized relapse rates (ARRs), time to discontinuation, time to first relapse (TTFR) and time to 24-week confirmed disability progression (CDP) or 24-week confirmed disability improvement (CDI; in patients with baseline Expanded Disability Status Scale [EDSS] score ≥2). Results After IPTW, ARR was similar for DMF (0.13) and NSIS (0.16; p = 0.29). There was no difference in TTFR between cohorts (hazard ratio [HR]: 0.98; p = 0.84). The DMF cohort experienced longer times to discontinuation (HR: 0.75; p = 0.001) and CDP (HR: 0.53; p = 0.001), and shorter time to CDI (HR: 1.99; p < 0.008), versus the NSIS cohort. Conclusion This analysis supports the use of DMF to treat patients with relapsing forms of MS, and may have implications for MS practices in countries where NSIS are commonly used to treat RRMS. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://biblio.ugent.be/publication/01HZ1M4D2YCVHWZ3D04Y5WY0SV; https://doi.org/10.1177/20552173241247182; https://biblio.ugent.be/publication/01HZ1M4D2YCVHWZ3D04Y5WY0SV/file/01HZ1M7MWBNTHPQYSV8J8T1CMG |
| DOI: |
10.1177/20552173241247182 |
| Availability: |
https://biblio.ugent.be/publication/01HZ1M4D2YCVHWZ3D04Y5WY0SV; https://hdl.handle.net/1854/LU-01HZ1M4D2YCVHWZ3D04Y5WY0SV; https://doi.org/10.1177/20552173241247182; https://biblio.ugent.be/publication/01HZ1M4D2YCVHWZ3D04Y5WY0SV/file/01HZ1M7MWBNTHPQYSV8J8T1CMG |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.F532FDE8 |
| Database: |
BASE |